Table 3

Sensitivity and subgroup analysis of the adjusted HRs of acarbose use for the risk reduction of colorectal cancer during the follow-up period in the cohort with diabetes

Acarbose use
>0 to <90 cDDD90 to 364 cDDD≥365 cDDD
HR95% CIHR95% CIHR95% CI
Sensitivity analysis
 Main model (unadjusted)0.860.76–0.990.740.63–0.870.480.39–0.60
 Additional covariates*
  Metformin0.910.79–1.040.790.67–0.930.510.41–0.63
  TZD0.930.81–1.060.840.71–0.990.550.44–0.69
  Insulin0.650.57–0.750.570.48–0.670.380.31–0.47
  Aspirin0.860.75–0.980.740.63–0.870.480.39–0.59
  Statin0.880.77–1.010.790.67–0.930.520.42–0.65
  NSAID0.860.76–0.990.740.63–0.880.480.39–0.60
Subgroup analysis
 Sex
  Male0.820.68–0.980.710.57–0.890.510.38–0.67
  Female0.920.76–1.120.780.62–0.980.450.33–0.63
 Age
  <50 years0.830.58–1.180.630.40–0.970.370.20–0.69
  ≥50 years0.860.74–0.990.770.65–0.920.500.40–0.63
 Diabetes duration
  <9 years0.850.68–1.060.730.55–0.970.520.34–0.78
  ≥9 years0.890.75–1.050.750.62–0.910.460.36–0.60
 Surveillance colonoscopy
  No0.870.76–0.990.750.63–0.880.470.37–0.58
  Yes0.840.43–1.650.640.27–1.530.860.36–2.04
  • *The unadjusted main models were adjusted for each additional listed covariate.